DV
Dividend Vision

IBRX — ImmunityBio, Inc.

ImmunityBio, Inc. (IBRX)

Total return is -78.1% over the past 11 years, 422.9 points behind SPY at 344.8%. Its deepest 1-year drawdown was 42.3%.

IBRX is an equity fund focused on ImmunityBio, Inc., a single-stock holding rather than a diversified ETF portfolio. The fund does not currently distribute dividends, making it unsuitable for income-focused investors seeking regular yield. This holding is oriented toward investors interested in direct exposure to the biotechnology sector, though the lack of diversification and absence of dividend distributions distinguish it from traditional dividend-focused ETF strategies.

IBRX key facts

Asset type
Stock
Asset class
Equity
Inception date
07/28/2015
Distribution frequency
None
Last close
$7.57
Market cap
$8,022,960,640
Average volume
4898700.0
Beta
0.125
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.94